Women on Farms Project calls for urgent ban on cyanamide pesticide
Image: Supplied
AGRICULTURE Minister John Steenhuisen has yet to disclose how his office would deal with increasing calls for a complete and immediate end to the production, export and use of cyanamide/Dormex for agricultural purposes, amid serious health risks to farmworkers.
Cyanamide, a Highly Hazardous Pesticide (HHP), according to Women on Farms Project (WFP) had lost its approval in the European Union since 2008, but is still produced by Alzchem in Germany from where it is exported to countries in the global South, including South Africa.
In South Africa, cyanamide is distributed by Philagro on behalf of Alzchem, according to WFP.
A memorandum by Women on Farms project is accepted by Schalk Reynolds from Philagro.
Image: Supplied
Scores of women farm workers and dwellers recently marched to Philagro's office in Somerset West to hand over a memorandum for the attention of Alzchem Group AG, to highlight their concerns.
'In 2019, WFP, a feminist South African non-governmental organisation, undertook a desk-top study which found that 67 pesticides that are already banned in Europe are still exported to and used in South Africa. Since the launch of its Double Standards campaign, WFP has been lobbying the South African government to ban these pesticides, while also demanding that European companies like Alzchem stop the production and export of pesticides that have been banned in the European Union because they are so harmful to human health.
"Farmwomen have stated that it is unjust that farm workers in South Africa, the majority of whom are women, are exposed to pesticides that have been banned in Europe," said WFP.
Video Player is loading.
Play Video
Play
Unmute
Current Time
0:00
/
Duration
-:-
Loaded :
0%
Stream Type LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text Color White Black Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Transparent Semi-Transparent Opaque
Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps
Reset
restore all settings to the default values Done
Close Modal Dialog
End of dialog window.
Advertisement
Video Player is loading.
Play Video
Play
Unmute
Current Time
0:00
/
Duration
-:-
Loaded :
0%
Stream Type LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text Color White Black Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Transparent Semi-Transparent Opaque
Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps
Reset
restore all settings to the default values Done
Close Modal Dialog
End of dialog window.
Next
Stay
Close ✕
WFP lamented that many farm women were exposed to Dormex/cyanamide without proper training, no proper protective equipment, were also not guaranteed water to wash their hands or even a toilet to relieve themselves while working.
'The European Food and Safety Authority (2010) found that even when proper protective equipment, masks, gloves, visors, hoods and rubber boots are used; operator exposure estimates exceeded acceptable levels by 6433%. The situation in South Africa is particularly dire as there is widespread non-compliance with the South African occupational health and safety legislation and a persistent lack of effective enforcement by labour inspectors,' the organisation added.
They want a formal meeting with Alzchem to discuss their concerns.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
21 hours ago
- The Star
Strict SA rules keep botox treatments safe, expert says
In South Africa, as botulinum toxin injections become increasingly popular for aesthetic treatments, a recent incident in the United States has sparked renewed concerns about their potential risks. It is revealed that a mother of three from Georgia suffered partial paralysis following what was presumed to be a routine procedure, highlighting the critical importance of seeking qualified medical professionals for these treatments. The woman developed severe migraines shortly after her injections, and within a day, she was hospitalised and unable to speak or function. Medical professionals later determined that she had experienced small strokes as a result of the procedure. While such extreme complications are exceedingly rare, this case has underscored the necessity of ensuring that injectable procedures are performed only by qualified and experienced practitioners in reputable clinics. Dr JD Erasmus, MBChB, BSc, a medical doctor specialising in aesthetics, pointed out that concerns about the safety of botulinum toxin are usually unnecessary, as long as the right procedures are followed. 'People hear the word 'toxin' and understandably get nervous. But iatrogenic botulism (caused by a medical treatment) after aesthetic treatments is extremely rare in medical clinics with qualified doctors who follow proper protocols and only inject trusted products from regulated manufacturers,' he explained. Erasmus elaborated on the extensive research supporting botulinum toxin as one of the most studied anti-ageing treatments in aesthetic medicine, demonstrating its efficacy in relaxing targeted facial muscles, rejuvenating the skin, and even alleviating tension headaches. 'In cosmetic treatments, it's used in very small, highly controlled doses by trained professionals. When done correctly, it stays where it's injected, does its job, and your body naturally breaks it down over time,' he assured. Incidences of iatrogenic botulism are uncommon, with the toxin generally staying localised to treatment areas. Overall, botulism in all its forms occurs in less than one in every 100 000 cases. Dr Erasmus said that globally, thousands undergo botulinum toxin procedures safely each day, with no recorded instances linked to aesthetic treatments in South Africa as of now. However, the risks of such complications escalate in regions with weaker regulations. Just two years ago, Turkey witnessed an extreme case where 71 individuals developed iatrogenic botulism from treatments at a single clinic, calling attention to the dangers of medical tourism in poorly regulated markets. 'That's the danger of medical or cosmetic tourism to locations with less stringent safety standards,' Dr Erasmus warned. 'You may not know what product is being used or who is injecting it, and following up with your practitioner can be challenging.' South African regulations help mitigate the risks often seen abroad. Botulinum toxin injections are classified as Schedule 4 medicines regulated by the South African Health Products Regulatory Authority (SAHPRA). Only licensed doctors registered with the Health Professions Council of South Africa (HPCSA) can administer these procedures, and strict guidelines are enforced regarding the purchase and use of these products. Clinics such as the Longevity Centre at RXME prioritise patient safety through rigorous protocols, this encompasses precise temperature-controlled storage of vials, sterilisation during mixing, and thorough documentation of each product's usage. Licensed practitioners are expected to evaluate patient suitability, accurately calculate doses for optimal results, and utilise only approved products sourced from authorised suppliers. Erasmus further emphasised the importance of patients doing their due diligence prior to treatment: 'Check your practitioner's HPCSA registration, ensure that the unopened product will be used in front of you, note the lot number, and establish a clear follow-up plan.' He reassured that ethical clinics encourage such inquiries, understanding the significance of informed patients. 'Ultimately, news stories from overseas should serve as lessons about the dangers of taking shortcuts rather than prompts for panic. Botulinum toxin boasts one of the best safety records in aesthetic medicine. In South Africa, selecting a qualified doctor and a reputable clinic virtually eliminates the risk of serious complications,' Erasmus concluded. [email protected] Saturday Star
IOL News
a day ago
- IOL News
Botox treatments in South Africa: what you need to know about safety
Botox is widely used as an anti-ageing treatment, but there are risks if patients opt for budget deals with unregistered clinics. Image: Cottonbro studio / Pexels A South African cosmetic treatment expert says there's no need for panic here following global concerns over a recent case in the United States where a woman was left partially paralysed after having routine botulinum toxin anti-ageing injections, commonly known as Botox. And while the mother of three survived from what doctors later said was a mild stroke, it set off warning bells among thousands of people who are increasingly turning to the treatment that targets facial muscles, tightens and rejuvenates the skin. Dr J D Erasmus, a general practitioner with a special interest in aesthetics and the Head of Aesthetics at the Longevity Centre at RXME, says fears of botulism from Botox injections are largely misplaced. Dr J D Erasmus says South Africans need to be more discerning when choosing where to have cosmetic treatments. Image: Supplied Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Next Stay Close ✕ 'People hear the word 'toxin' and understandably get nervous. But iatrogenic botulism (caused by a medical treatment) after aesthetic treatments is extremely rare in medical clinics with qualified doctors who follow proper protocols and only inject trusted products from regulated manufacturers,' he says. He adds that botulinum toxin is one of the most extensively studied anti-ageing treatments in aesthetic medicine. In addition to smoothing lines and wrinkles, the treatment is also known to relieve tension headaches. 'In cosmetic treatments, it's used in very small, highly controlled doses by trained professionals. When done correctly, it stays where it's injected, does its job, and your body naturally breaks it down over time. "The horror stories we hear are almost always linked to unqualified practitioners, dangerously high doses, and fake or unregistered products, and are not the work of reputable doctors in South Africa.' In cases of iatrogenic botulism from botulinum toxin injections, the toxin moves further than the treatment area and causes muscle weakness, which is an unusual complication rarely seen in aesthetic injections, he says. 'Globally, thousands of people undergo botulinum toxin procedures safely every day. According to our research, there have not been any recorded cases linked to aesthetic treatments in South Africa. 'Overseas, however, the risks increase where regulations are weaker. "In one extreme case in Turkey two years ago, 71 people developed iatrogenic botulism from botulinum toxin injections in just over a month, and 66 of those cases were traced to the same clinic." Erasmus says this latest scare highlights the dangers associated with medical or cosmetic tourism that's poorly regulated. 'You don't always know what product is being used, who is injecting it, or whether proper safety standards are being followed, and you can't always follow up with your practitioner if you have any concerns after the procedure. 'These types of incidents are important reminders to take your health seriously and choose a clinic you can trust. Before booking a treatment, check your practitioner's qualifications and reputation and make sure that the facility follows stringent product quality and safety regulations.'
IOL News
a day ago
- IOL News
Glenmore's R2bn claims against health service providers dismissed by Competition Tribunal
The decision comes after the Tribunal upheld exceptions filed by both the National Health Laboratory Service (NHLS) and AfroCentric Health, citing multiple deficiencies in Glenmore's case. Image: Supplied The Competition Tribunal has ruled against Glenmore Capital, dismissing its complaint regarding the alleged exclusion of its COVID-19 rapid antigen test kits from the South African public and private sectors. The decision comes after the Tribunal upheld exceptions filed by both the National Health Laboratory Service (NHLS) and AfroCentric Health, citing multiple deficiencies in Glenmore's case. Glenmore's complaint, originally lodged with the Competition Commission in August 2022, sought damages nearing R2 billion, claiming that NHLS and AfroCentric engaged in exclusionary practices that barred it from entering the market for COVID-19 test kits. The Commission, however, chose not to pursue the case, citing Glenmore's struggle to achieve market acceptance as a result of commercial factors, including delays in regulatory approval and a decrease in demand as the COVID-19 pandemic waned. Frustrated with the Commission's decision, Glenmore escalated the matter to the Tribunal. At a pre-hearing in December 2024, Glenmore was afforded an opportunity to amend its founding affidavit to address the concerns raised by NHLS and AfroCentric. Despite making amendments, both defendants argued that Glenmore's case remained fundamentally flawed. Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Next Stay Close ✕ In its defence, NHLS and AfroCentric articulated four primary exceptions, asserting that Glenmore's complaint lacked a valid cause of action, failed to properly identify the legal entities involved, lacked a clear market definition, and exceeded the Tribunal's jurisdiction due to the nature of the claims made. No valid cause of action: Glenmore's complaint failed to establish a legal basis under the Competition Act, lacking both legal and factual foundation. Glenmore's complaint failed to establish a legal basis under the Competition Act, lacking both legal and factual foundation. Improper citation of entities: Glenmore did not adequately identify which legal entity allegedly contravened the Act, despite having been given several opportunities to rectify this. Lack of proper market definition: The complaint failed to clarify the relevant market, with Glenmore shifting references between disparate health products without defining a cohesive product or geographic market. The complaint failed to clarify the relevant market, with Glenmore shifting references between disparate health products without defining a cohesive product or geographic market. Lack of jurisdiction and procedural issues: The Tribunal highlighted that it cannot award damages unless under consent orders and noted allegations outside the ambit of competition law, such as irregular procurement and insider trading. The Tribunal noted that Glenmore had been granted ample opportunity to clarify and bolster its case but ultimately failed to provide a coherent argument. With the exceptions upheld, Glenmore's complaint referral was dismissed in its entirety. BUSINESS REPORT
